Pre‐clinical studies with the native anti‐CD30 mAbs SGN‐30 and 5F11 had shown promising activity in vitro and in mouse models [79, 80, 81], but only demonstrated scarce anti‐tumor efficacy in patients [82, 83, 84]. Here, TNFRSF8 is linked to neoplasm.